Significance of viral status on recurrence of hepatitis B-related hepatocellular carcinoma after curative therapy: A meta-analysis

Hepatology Research

Volumn 44, Issue 7, 2014, Pages 750-760

  Qu, Li Shuai ^a   Liu, Jin Xia ^a   Kuai, Xiao Ling ^a   Xu, Zheng Fu ^a   Jin, Fei ^b   Zhou, Guo Xiong ^a  

^a NANTONG UNIVERSITY   (China)

^b Shanghai Xuhui Central Hospital   (China)

Author keywords

Curative therapy; Hepatitis B virus; Hepatocellular carcinoma; Recurrence

Indexed keywords

ANTIVIRUS AGENT; NUCLEOSIDE ANALOG;

ABLATION THERAPY; ANTIVIRAL THERAPY; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; META ANALYSIS; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROMOTER REGION; PUBLISHING; RECURRENCE RISK; SENSITIVITY ANALYSIS; VIRUS LOAD;

EID: 84903878897     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12172     Document Type: Article

References (43)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
3. Takayama T, Sekine T, Makuuchi M etal. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356: 802-807.
4. Shah SA, Cleary SP, Wei AC etal. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery 2007; 141: 330-339.
5. Ohkubo T, Yamamoto J, Sugawara Y etal. Surgical results for hepatocellular carcinoma with macroscopic portal vein tumor thrombosis. J Am Coll Surg 2000; 191: 657-660.
6. Nishikawa H, Inuzuka T, Takeda H etal. Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: a proposed new grading system for the ablative margin and prediction of local tumor progression and its validation. J Gastroenterol 2011; 46: 1418-1426.
7. Chen CJ, Yang HI, Su J etal. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
8. Yang HI, Yeh SH, Chen PJ etal. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 1134-1143.
9. Qu LS, Liu TT, Jin F etal. Combined pre-S deletion and core promoter mutations related to hepatocellular carcinoma: a nested case-control study in China. Hepatol Res 2011; 41: 54-63.
10. Kubo S, Hirohashi K, Tanaka H etal. Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma. Cancer 2000; 88: 1016-1024.
11. Hung IF, Poon RT, Lai CL, Fung J, Fan ST, Yuen MF. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol 2008; 103: 1663-1673.
12. Kim BK, Park JY, Kim Y etal. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int 2008; 28: 393-401.
13. Qu LS, Jin F, Huang XW, Shen XZ. High hepatitis B viral load predicts recurrence of small hepatocellular carcinoma after curative resection. J Gastrointest Surg 2010; 14: 1111-1120.
14. Liaw YF, Sung JJ, Chow WC etal. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531.
15. Kuzuya T, Katano Y, Kumada T etal. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol 2007; 22: 1929-1935.
16. Kubo S, Tanaka H, Takemura S etal. Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. Hepatol Res 2007; 37: 94-100.
17. Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma. Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. J Gastroenterol Hepatol 2010; 25: 657-663.
18. Chung GE, Kim W, Lee JH etal. Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy. J Gastroenterol Hepatol 2011; 26: 1638-1645.
19. Kubo S, Hirohashi K, Tanaka H etal. Virologic and biochemical changes and prognosis after liver resection for hepatitis B virus-related hepatocellular carcinoma. Dig Surg 2001; 18: 26-33.
20. Chen JD, Liu CJ, Lee PH etal. Hepatitis B genotypes correlate with tumor recurrence after curative resection of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2004; 2: 64-71.
21. Huang Y, Wang Z, An S etal. Role of hepatitis B virus genotypes and quantitative HBV DNA in metastasis and recurrence of hepatocellular carcinoma. J Med Virol 2008; 80: 591-597.
22. Xia F, Lai EC, Lau WY etal. High serum hyaluronic acid and HBV viral load are main prognostic factors of local recurrence after complete radiofrequency ablation of hepatitis B-related small hepatocellular carcinoma. Ann Surg Oncol 2012; 19: 1284-1291.
23. Yang T, Lu JH, Zhai J etal. High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study. Eur J Surg Oncol 2012; 38: 683-691.
24. Liang TJ, Mok KT, Liu SI etal. Hepatitis B genotype C correlated with poor surgical outcomes for hepatocellular carcinoma. J Am Coll Surg 2010; 211: 580-586.
25. Piao CY, Fujioka S, Iwasaki Y etal. Lamivudine treatment in patients with HBV-related hepatocellular carcinoma - using an untreated, matched control cohort. Acta Med Okayama 2005; 59: 217-224.
26. Shuqun C, Mengchao W, Han C etal. Antiviral therapy using lamivudine and thymosin alpha1 for hepatocellular carcinoma coexisting with chronic hepatitis B infection. Hepatogastroenterology 2006; 53: 249-252.
27. Yoshida H, Yoshida H, Goto E etal. Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma. Hepatol Int 2008; 2: 89-94.
28. Chuma M, Hige S, Kamiyama T etal. The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol 2009; 44: 991-999.
29. Koda M, Nagahara T, Matono T etal. Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function. Intern Med 2009; 48: 11-17.
30. Li N, Lai EC, Shi J etal. A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann Surg Oncol 2010; 17: 179-185.
31. Urata Y, Kubo S, Takemura S etal. Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 2011; 19: 685-696.
32. Wu CY, Chen YJ, Ho HJ etal. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 2012; 308: 1906-1914.
33. Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000; 232: 10-24.
34. Chon YE, Choi GH, Lee MH etal. Combined measurement of preoperative alpha-fetoprotein and des-gamma-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma. Int J Cancer 2012; 131: 2332-2341.
35. Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 2006; 26: 153-161.
36. Colombo M, Sangiovanni A. Etiology, natural history and treatment of hepatocellular carcinoma. Antiviral Res 2003; 60: 145-150.
37. Pan J, Clayton M, Feitelson MA. Hepatitis B virus X antigen promotes transforming growth factor-beta1 (TGF-beta1) activity by up-regulation of TGF-beta1 and down-regulation of alpha2-macroglobulin. J Gen Virol 2004; 85: 275-282.
38. Goto T, Yoshida H, Tateishi R etal. Influence of serum HBV DNA load on recurrence of hepatocellular carcinoma after treatment with percutaneous radiofrequency ablation. Hepatol Int 2011; 5: 767-773.
39. Wang C, Lu Y, Chen Y etal. Prognostic factors and recurrence of hepatitis B-related hepatocellular carcinoma after argon-helium cryoablation: a prospective study. Clin Exp Metastasis 2009; 26: 839-848.
40. Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Mullhaupt B, Clavien PA. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 2009; 96: 975-981.
41. Zhang CH, Xu GL, Jia WD, Ge YS. Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Int J Cancer 2009; 124: 2982-2988.
42. Baumert TF, Rogers SA, Hasegawa K, Liang TJ. Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest 1996; 98: 2268-2276.
43. Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology 2000; 31: 1037-1044.